anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a high quality org. solvent hardly contg. fine particles by distilling an org. solvent contg. fine particles, filtering the resulting distillate with a filter having a specified pore diameter and carrying out sealing with a clean gas satisfying specified conditions. CONSTITUTION:An org. solvent contg. fine particles is distilled and the resulting distillate is filtered by passing through a filter having <=1mum pore diameter to remove the fine particles. An apparatus for holding the filtered distillate such as a cooler, a pipe line or a storage tank is sealed with a clean inert gas contg. <=350, preferably <=35 fine particles of >=0.5mum diameter per 1l gas, e.g., CO2 or He. Since the org. solvent is first freed of the fine particles and then isolated from the air to prevent fine particles from entering the solvent, a high quality org. solvent hardly contg. fine particles and used in the production of a semiconductor for IC, etc., is obtd.
An example of a display system includes a sensor, a projector, and control means. The sensor senses user information for calculating a state regarding sleep of a user. The user information is, for example, biological information such as pulse. The projector projects and displays a predetermined image. The projector, for example, projects the image upward to project and display the image on the ceiling. The control means controls the projector in accordance with a state regarding sleep, which is calculated on the basis of the user information.
There are provided PVP-PLA block copolymers as defined in Formula (I): I wherein, x is an initiator alcohol having a boiling point greater than 145°C, n is, on average, from 20 and 40, and m is, on average, from 10 and 40, wherein the block copolymers have a number average molecular weight (M n ) of at least 3000 Da. Polymers demonstrating flexibility in formulating multiple low-solubility active pharmaceutical ingredients (APIs) are described. Liquid and dry pharmaceutical formulations comprising an API are described, along with delivery methods, uses, and kits. APIs may include, e.g. flurbiprofen, celecoxib, acetaminophen, or propofol. Also provided is a method of synthesizing the PVP-PLA block copolymers by (i) initiating polymerization of D,L-Lactide from the initiator alcohol x to form poly(lactic acid), adding a xanthate to form a PLA macroinitiator, and polymerizing NVP onto the PLA macroinitiator, by controlled polymerization, to form the block copolymer compound of Formula (I).
The invention discloses a preparation method of bear bile, which comprises the following steps: incising a wound on the gall bladder of a bear, forming a fistula with muscular tissues and binding up; and extruding a fistula orifice after healing so as to collect the bile. The method can be used for non-continuous, timing, quantitative and long-term collection, and can avoid affecting the utilization of the bile of the bear. The invention discloses high-quality bear bile powder and the preparation method thereof. The bear bile powder shows bright yellow fluorescence under a 365nm ultraviolet lamp and has three chromatographic peaks under 198nm. The preparation method of the powder comprises the steps of standing the bile, separating and drying the powder, and then crushing and screening the powder so as to get the bear bile powder. The prepared bear bile powder is pure in color and luster of appearance, high in the content of tauroursodeoxycholic acid, does not absorb moisture and is convenient to store, transport and process.
A method and system of tracking and analyzing data during a medical procedure is provided. A wearable sensor (e.g. EEG system to obtain EEG signals) is worn by a practitioner, where the wearable sensor covers a body part of the practitioner. The practitioner performs a medical procedure on a person. The medical procedure is video recorded. A computer system digitally registers the medical procedure by registering (i) the digital data from the wearable sensor, and (ii) the digital data of the video recording. The computer system synchronizes the registered digital data of (i) and (ii) into a synchronized data set, and sections are then identified for the synchronized data set. The computer system generates sensor data maps from the synchronized data set and the identified sections, which are then useful for the practitioner, colleagues and other learners for feedback and training purposes.
BACKGROUND: Posthepatectomy liver failure (PHLF) remains a life-threatening complication after hepatectomy. To reduce PHLF, a preoperative assessment of liver function is indispensable. For this purpose, 99mTc-mebrofenin hepatobiliary scintigraphy with SPECT (MSPECT) can be used. The aim of the current study was to evaluate the predictive value of MSPECT for PHLF in patients with non-colorectal liver tumors (NCRLT) compared to patients with colorectal liver metastasis (CRLM) undergoing extended liver resection.
METHODS: We included all patients undergoing extended liver resections via two-stage procedures between January 2019 and December 2021 at the University Medical Center Hamburg-Eppendorf, Germany. All patients received a preoperative MSPECT.
RESULTS: Twenty patients were included. In every fourth patient, PHLF was observed. Four patients had PHLF grade C. There were no differences between patients with CRLM and NCRLT regarding PHLF rate and future liver remnant (FLR) volume. Patients with CRLM had higher mebrofenin uptake in the FLR compared to those with NCRLT (2.49%/min/m2 vs. 1.51%/min/m2; p = 0.004).
CONCLUSION: Mebrofenin uptake in patients with NCRLT was lower compared to those patients with CRLM. However, there was no difference in the PHLF rate and FLR volume. Cut-off values for the mebrofenin uptake might need adjustments for different surgical indications, surgical procedures, and underlying diseases.
LSVT LOUD® is a therapy program which requires four sessions per week for 4 weeks by a speech and language therapists with a certification in Lee Silverman Voice Therapy. Each session lasted 50-60 min.
Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food.
PURPOSE:To obtain an extracted raw material without lowering saponin content, by contacting raw material of AMACHAZURU (Gynostemma pentaphyllum) selected from raw stalks and leaves, etc., of AMACHAZURU with a basic or acidic aqueous solution. CONSTITUTION:Raw material of AMACHAZURU selected from raw stalks, leaves or their cut product of AMACHAZURU is made to contact with an aqueous solution of a base or acid for 0.5-24hr. The pH of the basic aqueous solution is >=10 (e.g. NaOH) and that of the acidic aqueous solution is <=3 (e.g. 0.1-2N HCl). The temperature of the aqueous solution is between the freezing point and 40 deg.C, preferably 0-35 deg.C. The aqueous solution is used at least in an amount to be sufficient to wet the whole surface of the raw material, i.e. 5-200ml per 1g of the raw material. A raw material of AMACHAZURU containing inactivated saponin-hydrolyzing enzyme can be produced by the contacting treatment and the raw material can be used as a raw material for the production of an extract.
Approximately 250 subjects to receive 3 doses of bOPV administered at approx. 6, 10, 14 weeks of age and an nOPV2-002 challenge at approx. 18 weeks of age.
Patients will take a placebo by mouth prior to and including the morning of surgery. If bloods tests done at the start of study show that the patients have a low (\< or = 30 ng/ml) Vitamin D level, patients will be given 2 placebo tablets to take once a week until surgery. If baseline Vitamin D level is \> 30 ng/ml, patients will be given on placebo tablet to take once a day until surgery.
Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
<P>PROBLEM TO BE SOLVED: To provide a compound exhibiting excellent conglutinant effect for ectocornea injury in subocular region.  <P>SOLUTION: The tPA (tissue plasminogen activator) exhibits excellent ectocornea extension promoting action. The ectocornea injury is corneal ulcer, ectocornea ablation, keratitis, dry eye, keratoconjunctivitis sicca, xerophthalmia, chronic superficial keratitis, corneal erosion or prolonged corneal epithelial loss. The dosage form is an ophthalmic solution or an ophthalmic ointment. The ectocornea injury therapeutic agent is administrated orally or parenterally.  <P>COPYRIGHT: (C)2004,JPO
INTRODUCTION: Craniosynostosis, marked by premature skull suture closure, manifests as isolated or syndromic cases. While isolated cases are more common, syndromic craniosynostoses are associated with a range of complications. This study aims to compare postoperative outcomes in isolated and syndromic craniosynostosis, hypothesizing greater complications in the latter.
MATERIALS AND METHODS: A case-control study was conducted with 30 pediatric patients with isolated (Group C) and syndromic (Group S) craniosynostosis undergoing surgery. Data on demographics, operative details, blood product transfusions, and postoperative complications were analyzed. Statistical analysis employed Chi-square, Fisher exact tests, and Mann-Whitney U tests.
RESULTS: Perioperative bleeding and postoperative packed red blood cell (PRBC) transfusions were significantly higher in isolated cases. Morbidity analysis, including reoperation, massive bleeding, infection, hydrocephalus, and seizures indicated higher rates in syndromic cases. The rates of postoperative morbidities were 30% in syndromic and 10% in isolated cases (p = 0.053). Correlations revealed a low positive association between body weight and both PICU and hospital stays. Additionally, a low positive correlation was found between perioperative PRBC transfusion amount and PICU length of stay. The total number of morbidities showed a moderate positive correlation with PICU length of stay and a low positive correlation with hospital length of stay.
CONCLUSION: Isolated craniosynostosis cases exhibited higher perioperative bleeding and PRBC transfusions, potentially influenced by surgery at an earlier age. Although complications tended to be elevated in syndromic cases, no significant differences were observed. This study underscores the necessity for meticulous perioperative care, emphasizing individualized approaches considering age-related factors and associated complications in managing craniosynostosis cases.
Lipid-rich diet is the major cause of obesity, affecting 13% of the worldwide adult population. Obesity is a major risk factor for metabolic syndrome that includes hyperlipidemia and diabetes mellitus. The early phases of metabolic syndrome are often associated with hyperexcitability of peripheral small diameter sensory fibers and painful diabetic neuropathy. Here, we investigated the effect of high-fat diet-induced obesity on the activity of dorsal root ganglion (DRG) sensory neurons and pain perception. We deciphered the underlying cellular mechanisms involving the acid-sensing ion channel 3 (ASIC3). We show that mice made obese through consuming high-fat diet developed the metabolic syndrome and prediabetes that was associated with heat pain hypersensitivity, whereas mechanical sensitivity was not affected. Concurrently, the slow conducting C fibers in the skin of obese mice showed increased activity on heating, whereas their mechanosensitivity was not altered. Although ASIC3 knockout mice fed with high-fat diet became obese, and showed signs of metabolic syndrome and prediabetes, genetic deletion, and in vivo pharmacological inhibition of ASIC3, protected mice from obesity-induced thermal hypersensitivity. We then deciphered the mechanisms involved in the heat hypersensitivity of mice and found that serum from high-fat diet-fed mice was enriched in lysophosphatidylcholine (LPC16:0, LPC18:0, and LPC18:1). These enriched lipid species directly increased the activity of DRG neurons through activating the lipid sensitive ASIC3 channel. Our results identify ASIC3 channel in DRG neurons and circulating lipid species as a mechanism contributing to the hyperexcitability of nociceptive neurons that can cause pain associated with lipid-rich diet consumption and obesity.
Ample evidence documents that supported employment is an effective strategy for improving the vocational outcomes of persons with schizophrenia and other severe mental illnesses. However, a significant amount of clients receiving supported employment services work little or not at all. With respect to factors that may influence the work outcomes of persons participating in supported employment programs, cognitive functioning appears to be potentially important. Cognitive impairment in persons with severe mental illness (SMI) is strongly correlated with functional adjustment in the community and has been shown to be correlated with work, both contemporaneously and prospectively. Studies have demonstrated that clients who did not receive the full benefits of supported employment had more deficits in executive functioning, memory, and psychomotor speed than those clients who had better work outcomes.

The current study will use a computerized cognitive training program that will be administered by a cognitive trainer. The program consists of 24 training modules (each one takes about one hour to complete). Clients in an SEP who have been unable to maintain a job that they acquired while in the program can participate in the research. Clients who have agreed to participate in the research project will be randomly assigned to either receive the computerized training and supported employment services (CT-SES) or supported employment services (SES) without the training (i.e., treatment-as-usual-condition). Both research groups will receive the same baseline, three-month, and 12-month follow up interviews that will consists of a brief clinical and neuropsychological evaluation, an assessment of problems associated with finding or maintaining employment, and employment outcomes while enrolled in the study. In addition, both groups will receive a telephonic interview at 18 and 24 months to assess their employment outcomes (clinical and neurological information will not be collected at 18 or 24 months).
Temozolomide (TMZ), a DNA alkylating agent, has become the primary treatment for glioma, the most common malignancy of the central nervous system. Although TMZ-containing regimens produce significant clinical response rates, some patients inevitably suffer from inferior treatment outcomes or disease relapse, likely because of poor chemosensitivity of glioma cells due to a robust DNA damage response (DDR). GINS2, a subunit of DNA helicase, contributes to maintaining genomic stability and is highly expressed in various cancers, promoting their development. Here, we report that GINS2 was upregulated in TMZ-treated glioma cells and co-localized with γH2AX, indicating its participation in TMZ-induced DDR. Furthermore, GINS2 regulated the malignant phenotype and TMZ sensitivity of glioma cells, mostly by promoting DNA damage repair by affecting the mRNA stability of early growth response factor 1 (EGR1), which in turn regulates the transcription of epithelial cell-transforming sequence 2 (ECT2). We constructed a GINS2-EGR1-ECT2 prognostic model, which accurately predicted patient survival. Further, we screened Palbociclib/BIX-02189 which dampens GINS2 expression and synergistically inhibits glioma cell proliferation with TMZ. These findings delineate a novel mechanism by which GINS2 regulates the TMZ sensitivity of glioma cells and propose a promising combination therapy to treat glioma.
IP vancomycin 1g every 5 days combined with oral moxifloxacin 400mg QD. The duration of treatment was based on ISPD guideline recommendations.
Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
PURPOSE:An enteric coating composition, obtained by incorporating a water- dispersible copolymer obtained by emulsion polymerizing ethyl acrylate with methacrylic acid with triethyl citrate as a plasticizer and exhibiting no change with time. CONSTITUTION:An enteric coating composition consisting essentially of a water- dispersible copolymer obtained by emulsion polymerizing ethyl acrylate with methacrylic acid and triethyl citrate. Althought the above-mentioned water- dispersible copolymer is used in an enteric coating, the addition of a plasticizer is indispensable to prevent the cracking and embrittling of the coating layer. Polyethylene glycol, etc., has been used, but in the case of the polyethylene glycol, the delay in disintegration time is sometimes recognized with time if a coating formulation is filled in a gelatin capsule. If triacetin is used, there is a problem of acetic acid smell formation with time. However, the use of the triethyl citrate as a plasticizer is capable of eliminating the above-mentioned problem.
1498261 Influenza vaccines SANDOZ Ltd 13 Jan 1975 [14 Jan 1974] 1290/75 Heading A5B The haemagglutinin and neuramuridase components are isolated from influenza virus by treating the virus in an aqueous medium with a cationic detergent to selectively solubilise such components, and separating the resulting solubilised such components from residual sub-viral particles. The virus concentrate may have a pH of from 6.5 to 8.5 and may inactivated with formaldehyde prior to the addition of the cationic detergent. After addition of the cationic detergent, the resulting mixture is preferably allowed to stand for 30 minutes to 16 hours at 4‹C to 37‹C. Influenza vaccines comprise a mixture of the haemagglutinin and neuramuridase components of an influenza virus, in the substantial absence of other components of the influenza viral particle in association with -an inertliquid diluent such as physiological saline optionally phosphate buffered. The vaccine may additionally comprise a preserving or inactivating agent such as formaldehyde and/or an immunological adjuvant such as aluminium hydroxide or aluminium phosphate. The influenza virus may be an influenza Type A, A 1 , A 2 or B virus, strain A2/Aichi/68, MRC-2 (recombination of Type A2/England/42/72), MRC-11 (recombination of Type A2/Port Chalmers/73), A/Pasteur/30C (Mutagrip), or B/Mass/67.
[GB1498261A]
The invention belongs to the field of biological medicine, and relates to a method for treating diabetes. The invention provides application of a composition containing IL-6 and bone marrow mesenchymal stem cells in preparing a medicament for treating/preventing diabetes. The research of the inventor finds that the effect of the bone marrow mesenchymal stem cells on treating the type I diabetes is far less than that of the mesenchymal stem cells from pancreatic exocrine glands, and the bone marrow mesenchymal stem cells and the islet beta cells are co-cultured (directly contacted), so that the bone marrow mesenchymal stem cells have a killing effect on the islet beta cells. This has led to the bone marrow mesenchymal stem cells not being an ideal source of cells for the treatment of type i diabetes. However, the inventors have not been limited to such a situation, but have conducted continuous research and research to find that the effect of treating type i diabetes can be greatly improved by adding IL-6 to mesenchymal stem cells. Thereby overcoming the technical obstacle that the effect of the bone marrow mesenchymal stem cells for treating the type I diabetes is not good, and expanding the cell source for treating the type I diabetes. The mesenchymal stem cells of the bone marrow can be more easily obtained and widely sourced compared with the mesenchymal stem cells from the exocrine pancreatic gland, and can be used for clinic. Has very good practical significance.
FIELD: medicine, preparative biochemistry. SUBSTANCE: invention relates to methods for isolation of protein fractions, in part, high density lipoprotein (HDLP) fraction from plasma or serum blood and can be used for determination of fractional-component composition of lipoproteins in diagnosis of dyslipoproteinemia. Plasma or serum blood samples are heated at temperature 70-100 C for time providing milk color of samples. Formed protein gel is milled, centrifuged and supernatant containing fraction of HDLP particles is taken off. The most optimal result is obtained if samples of plasma or serum blood are heated at temperature 80-90 C for 2-10 min. Method provides reduction of labor intensity and time of process, it doesn't require the expensive cost equipment and chemically active reagents, it doesn't pollute the final preparative form, it doesn't destroy nativity of HDLP particles and it doesn't distort results of analysis of fractional-component composition of lipoproteins. EFFECT: improved isolation method. 4 cl, 1 tbl, 2 dwg, 2 ex
Control of infection and bacterial colonisation constitutes a continuing challenge in patients with burns. Prevention of microbial contamination and infection is vital for burn wound care as bacterial presence can result in excessive inflammatory reactions, delayed re-epithelialisation, impaired matrix remodelling and bacteraemia. A novel method to decrease the likelihood of infection and to help cure wounds is cold atmospheric plasma (CAP). CAP has been shown in vitro to kill a wide range of pathogenic bacteria.

This safety study aims to demonstrate the safety, efficacy and efficiency of CAP for burn wound treatment. Intact skin of volunteers will be CAP treated. Local skin reaction (blister formation, pain, itching), erythema, local skin temperature, trans epidermal water loss (TEWL) and reduction of the bacterial load wil be monitored.